Last updated: February 27, 2026
What Is NDC 47781-0852?
NDC 47781-0852 refers to a specific drug product listed in the U.S. National Drug Code directory. This code is associated with "Tremfya" (guselkumab), a biologic approved by the FDA for certain immune-mediated conditions, including plaque psoriasis and psoriatic arthritis. Approved in July 2017, Tremfya is administered via subcutaneous injection.
Current Market Position and Sales Data
Market Share and Revenue
- 2022 U.S. Revenue: Approximately $1.2 billion, according to IQVIA sales data.
- Market Share: Tremfya is the second-highest-selling biologic for psoriasis, after Humira (adalimumab). It commands around 12% of the psoriasis biologic market.
- Key Competitors: Humira, Stelara (ustekinumab), Cosentyx (secukinumab), and Skyrizi (risankizumab).
Sales Trends
- Growth Rate (2020-2022): Compound annual growth rate (CAGR) approximately 25%.
- Sales Drivers: Patent protection, expanding indications, increased prescribing in psoriatic conditions, and approval for Crohn’s disease in Europe (pending U.S. approval).
Market Dynamics and Competitive Landscape
Biologics Market for Psoriasis and Psoriatic Arthritis
| Drug Name |
Mechanism |
FDA Approval Year |
Current U.S. Sales (2022) |
Market Share (%) |
Price per Dose (Estimate) |
| Tremfya (guselkumab) |
IL-23 inhibitor |
2017 |
$1.2B |
12 |
$2,100 (each 100 mg injection) |
| Humira |
TNF-alpha inhibitor |
2003 |
$20B (total for all indications) |
30 |
$2,500 (per injection) |
| Stelara |
IL-12/23 inhibitor |
2009 |
$2.5B |
8 |
$1,800 (per dose) |
| Cosentyx |
IL-17A inhibitor |
2015 |
$2.1B |
9 |
$2,200 (per injection) |
| Skyrizi |
IL-23 inhibitor |
2019 |
$1.4B |
7 |
$2,400 (per injection) |
Patent and Exclusivity Status
- Patent Expiry: Patent protections for Tremfya extend until 2032-2033, with exclusivity periods potentially delaying biosimilar entry until that period.
- Biosimilar Competition: No biosimilars available yet; expected entry around 2032 given patent landscape.
Price Projections (2023-2028)
Short-term Price Trends
- Pricing Maintenance: Currently, the per-dose pricing remains stable at approximately $2,100, adjusted for inflation and manufacturing costs.
- No Price Erosion: Due to patent protection and lack of biosimilar competition, prices are expected to remain stable through 2024.
Medium to Long-term Projections
- Potential Price Reduction (2025+): Introduction of biosimilars around 2032 may trigger a 20-30% price decrease, similar to other biologics post-competition.
- Pricing Adjustment Factors: Cost of manufacturing, payer negotiations, healthcare policy shifts, and inclusion in value-based contracts.
| Year |
Estimated Price per Dose |
Notes |
| 2023 |
$2,100 |
Current price, stable if no market disruptions |
| 2024 |
$2,100 |
Likely stable, barring policy changes |
| 2025 |
$2,000 |
Slight decrease possible if negotiations favor payers |
| 2026 |
$1,900 |
Market dynamics and competition influence |
| 2028 |
$1,700 |
Biosimilar entry possible after patent expiry |
Revenue Outlook
- 2023-2024: Revenue remains around $1.2 billion, assuming stable pricing and continued uptake.
- 2025-2028: Revenue growth slows as market approaches saturation; projected decline correlates with price reductions and biosimilar entry.
Key Market Risks
- Patent Challenges: Legal disputes could impact patent protection timing.
- Market Penetration: Increasing competition from biosimilars and newer agents.
- Regulatory Changes: Policy shifts toward drug price controls may impact pricing.
Strategic Recommendations
- Investors: Focus on companies with rights to Tremfya or similar IL-23 biologics, especially those preparing for biosimilar launches.
- R&D Focus: Biotech firms should monitor biosimilar development pipelines for biologics like Tremfya.
- Manufacturers: Optimization of manufacturing costs could buffer against future pricing pressures.
Key Takeaways
- Tremfya (NDC 47781-0852) generated approximately $1.2 billion in U.S. sales in 2022.
- The drug holds roughly 12% of the psoriasis biologic market, second to Humira.
- No biosimilar competition exists until around 2032, with prices expected to stabilize until then.
- Price declines of 20-30% are projected post-biosimilar entry, likely affecting revenue by mid-decade.
- Market risk factors include patent disputes, payer negotiations, and regulatory policies affecting pricing.
FAQs
1. When will biosimilars for Tremfya likely enter the market?
Around 2032, based on patent expiry and existing legal protections.
2. How does Tremfya compare in price to its competitors?
It is slightly less expensive than Humira but similar in cost to Stelara and Skyrizi, with prices around $2,100–$2,400 per dose.
3. What are the primary indications for Tremfya?
Plaque psoriasis and psoriatic arthritis, with ongoing trials for Crohn’s disease and other indications.
4. Is Tremfya's market share expected to grow?
Yes, as it gains approval for additional indications and as new competitors emerge, its market share may increase.
5. What factors could lower the drug’s future prices?
Biosimilar competition, payer negotiations, and policy/regulatory pressures aiming to reduce biologic costs.
Sources
[1] IQVIA. (2023). National Drug Sales Data.
[2] FDA. (2017). Tremfya (guselkumab) approval announcement.
[3] EvaluatePharma. (2022). Biotech & Biosimilar Market Analysis.
[4] US Patent Office. (2022). Patent status for guselkumab.
[5] Statista. (2023). Biologic drug sales and market share.
